Chen Jiaoquan, Li Huaping, Zhu Huilan
Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, People's Republic of China.
Clin Cosmet Investig Dermatol. 2021 Dec 30;14:1913-1917. doi: 10.2147/CCID.S342401. eCollection 2021.
Chronic actinic dermatitis (CAD) is a rather rare photosensitive disease characterized by a persistent eczematous eruption in sun-exposed sites. The pathogenesis of CAD has not been completely elucidated. The clinical treatment of CAD is still challenging and not standardized. Some patients with severe CAD have achieved satisfactory clinical results with dupilumab when conventional therapies have failed. We herein report the case of a 45-year-old male with severe CAD who responded rapidly to combined treatment with dupilumab (600 mg for 1 week, and then 300 mg every 2 weeks) in 2 months. The patient experienced continuous improvement and no side effects from dupilumab (300 mg every month), having ceased other systemic medications. Dupilumab could be considered as an alternative or adjunctive treatment for CAD.
慢性光化性皮炎（CAD）是一种较为罕见的光敏性疾病，其特征为在暴露于阳光的部位出现持续性湿疹样皮疹。CAD的发病机制尚未完全阐明。CAD的临床治疗仍然具有挑战性且未标准化。当传统疗法失败时，一些重度CAD患者使用度普利尤单抗取得了满意的临床效果。我们在此报告一例45岁重度CAD男性患者，其在2个月内对度普利尤单抗联合治疗（第1周600mg，之后每2周300mg）反应迅速。该患者病情持续改善，在停用其他全身用药后，使用度普利尤单抗（每月300mg）未出现副作用。度普利尤单抗可被视为CAD的一种替代或辅助治疗方法。
